Navigation Links
ADVENTRX Pharmaceuticals Announces Closing of Financing
Date:10/9/2009

SAN DIEGO, Oct. 9 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it has completed the previously announced sale of shares of its Series D convertible preferred stock pursuant to a registered direct offering to institutional investors, representing gross proceeds to ADVENTRX of approximately $11.3 million. ADVENTRX plans to use the net proceeds from the offering to fund its operations during the FDA review period of an ANX-530 NDA and to continue development of ANX-514, and for general corporate purposes.

The preferred stock is convertible into shares of ADVENTRX's common stock at the option of the investors at a conversion price of $0.18805 per share and will accrue a 4.25660% cumulative dividend until October 9, 2020. If the convertible preferred stock is converted at any time prior to October 9, 2020, ADVENTRX will pay the holder an amount equal to the total dividend that would accrue on the convertible preferred stock from the conversion date through October 9, 2020, or $468.23 per $1,000 stated value of preferred stock converted, less any dividend payments made with respect to the converted preferred stock. Approximately $5.3 million of the gross proceeds will be placed in an escrow account, which amounts will be released to make the dividend and other payments described above. The investors also will receive warrants to purchase an aggregate of 19,800,000 shares of ADVENTRX's common stock. The warrants will have an exercise price of $0.1468 per share and are exercisable at any time after the closing of the transaction and before the fifth anniversary of the initial exercise date.

The convertible preferred stock and warrants were sold by ADVENTRX pursuant to an effective registration statement on Form S-1 filed with the Securities and Exchange Commission ("SEC"). A prospectus relating to the offering was filed with the SEC on October 6, 2009. Rodman & Renshaw, LLC, a wholly owned subsidiary of Rodman & Renshaw Capital Group, Inc. (NasdaqGM: RODM), acted as the exclusive placement agent for the transaction.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The securities may only be offered by means of a prospectus. Copies of the prospectus can be obtained directly from Rodman & Renshaw, LLC at 1251 Avenue of the Americas, 20th Floor, New York, NY 10020, or from the SEC's website at www.sec.gov.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the safety of existing cancer treatments. More information can be found on the Company's web site at www.adventrx.com.

Forward Looking Statement

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that ADVENTRX fails to submit an ANX-530 NDA, whether by December 31, 2009 or at all; the risk the FDA will determine that ANX-530 and Navelbine® are not bioequivalent or for the FDA to require additional preclinical work and/or clinical activities to support the submission or approval of an ANX-530 NDA; difficulties or delays in manufacturing, obtaining regulatory approval for and marketing ANX-530, including validating commercial manufacturers and suppliers; the risk that ADVENTRX's common stock will be delisted by the NYSE Amex, including as a result of failing to maintain sufficient stockholders' equity or a sufficient stock price; the risk that the provisions of Delaware General Corporation Law will prohibit ADVENTRX from making the cumulative dividend and other payments due its Series D convertible preferred stock (or to the holders thereof), which may be a breach of its certificate of incorporation or other contractual obligations and expose ADVENTRX to corresponding liability; the risk that ADVENTRX will be unable to raise sufficient additional capital to commercialize ANX-530 or to continue the development of ANX-514; the risk that the performance of third parties on whom ADVENTRX relies to conduct its studies or evaluate the data may be substandard, or they may fail to perform as expected; and other risks and uncertainties more fully described in ADVENTRX's press releases and in the prospectus relating to this offering that was filed with the Securities and Exchange Commission on October 6, 2009. ADVENTRX's public filings with the Securities and Exchange Commission are available at www.sec.gov.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to update any forward-looking statement as set forth in this press release to reflect events or circumstances arising after the date on which it was made.

SOURCE ADVENTRX Pharmaceuticals, Inc.


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
2. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
3. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
4. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
5. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
6. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
7. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
8. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
9. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
10. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
11. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... -- According to a new market research report "Clinical Decision ... Standalone), Model (Knowledge-Based), Type (Therapeutic, Diagnostic), User Interactivity (Active, Passive), Application - ... reach USD 1,519.2 Million by 2021 from USD 856.3 Million in 2016, ... ... MarketsandMarkets Logo ...
(Date:12/7/2016)... Dec. 7, 2016  Organovo Holdings, Inc. (NASDAQ: ... company focused on delivering scientific and medical breakthroughs ... Chairman and Chief Executive Officer Keith Murphy ... Wednesday, December 14, 2016 at 1:00 p.m. Eastern ... not yet familiar with the Company, an informational ...
(Date:12/7/2016)... According to the latest market ... Study on Multiplex Detection Immunoassay: North America to Dominate ... detection immunoassay market is expected to witness a CAGR of ... ...      (Logo: http://photos.prnewswire.com/prnh/20161114/438683LOGO) ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... OCTOBER XX, 2016 (PRWEB) (PRWEB) December 07, 2016 ... ... A new study entitled “Canine Filamentous Dermatitis Associated with Borrelia Infection” ... dogs. The study was published in the prestigious Journal of Veterinary Science & ...
(Date:12/7/2016)... ... ... Delete® - Tattoo Removal and Laser Salon Offers Delightful Holiday Deals On ... 33% Off Botox® and Juvederm® Products Now Through December 31, 2016 , Delete® - ... on Botox® and Juvederm® just in time for the holiday party season. , ...
(Date:12/7/2016)... ... December 07, 2016 , ... "ProBrand Flip allows FCPX editors ... said Christina Austin - CEO of Pixel Film Studios. , ProBrand Flip includes 30 ... drop zones. Editors can select from a variety of flip book animations. In Addition, ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... “The Road ... is an everyday trial, not a one hour a week showing of hands. “The ... businessman. , Tom begins, “Perhaps you are familiar with the brass ring that you ...
(Date:12/7/2016)... ... (PRWEB) December 07, 2016 , ... ... individuals impacted by cerebral cavernous angiomas, was awarded a grant from the Julian ... engagement program. New Mexico has more people with cavernous angioma than anywhere in ...
Breaking Medicine News(10 mins):